Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion

Current Medicinal Chemistry

Volumn 22, Issue 19, 2015, Pages 2360-2374

  Ojo, Diane ^a,b,c   Wei, Fengxiang ^d,e   Liu, Yun ^f   Wang, Enli ^g   Zhang, Hongde ^h   Lin, Xiaozeng ^a,b,c   Wong, Nicholas ^a,b,c   Bane, Anita ^a   Tang, Damu ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d Longgang Maternal and Child Health Hospital of Shenzhen   (China)

^e ZUNYI MEDICAL UNIVERSITY   (China)

^f NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^g Shenzhen Maternity and Child Healthcare Hospital   (China)

^h Central Hospital of Longgang District   (China)

Author keywords

Breast cancer; Breast cancer stem cells; Endocrine therapy; Estrogen receptor; Tamoxifen; Tamoxifen resistance

Indexed keywords

ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH4 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SONIC HEDGEHOG PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; BREAST CANCER STEM CELL; CANCER RESISTANCE; CANCER THERAPY; GENE MUTATION; HUMAN; MCF 7 CELL LINE; PROTEIN DEGRADATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL EXPANSION; WNT SIGNALING PATHWAY; BREAST NEOPLASMS; CANCER STEM CELL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR STRUCTURE; NEOPLASTIC STEM CELLS; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 84937037947     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150416095744     Document Type: Review

References (193)

1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136, E359-386.
2. Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature, 2000, 406, 747-752.
3. Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Thorsen, T.; Quist, H.; Matese, J.C.; Brown, P.O.; Botstein, D.; Eystein Lønning, P.; Børresen-Dal, A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A., 2001, i, 10869-10874.
4. Clark, G.M.; Osborne, C.K.; McGuire, W.L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol., 1984, 2(10), 1102-1129.
5. Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol., 1999, 17(5), 1474-1481.
6. Korach, K.S.; Couse, J.F.; Curtis, S.W.; Washburn, T.F.; Lindzey, J.; Kimbro, K.S.; Eddy, E.M.; Migliaccio, S.; Snedeker, S.M.; Lubahn, D.B.; Schomberg, D.W.; Smith, E.P. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog. Horm. Res., 1996, 51, 159-186.
7. Eeckhoute, J.; Carroll, J.S.; Geistlinger, T.R.; Torres-Arzayus, M.I.; Brown, M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev., 2006, 20, 2513-2526.
8. Musgrove, E.A.; Caldon, C.E.; Barraclough, J.; Stone, A.; Sutherland, R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer, 2011, 11(8), 558-572.
9. Dong, L.; Wang, W.; Wang, F.; Stoner, M.; Reed, J.C.; Harigai, M.; Samudio, I.; Kladde, M.P.; Vyhlidal, C.; Safe, S. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J. Biol. Chem., 1999, 274(45), 32099-32107.
10. Seeger, H.; Wallwiener, D.; Mueck, A.O. Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci., 2006, 78(13), 1464-1468.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365(9472), 1687-1717.
12. Musgrove, E.A.; Sutherland, R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer, 2009, 9(9), 631-643.
13. Ring, A.; Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer, 2004, 11(4), 643-658.
14. García-Becerra, R.; Santos, N.; Díaz, L.; Camacho, J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int. J. Mol. Sci., 2012, 14(1), 108-145.
15. Sweeney, E.E.; McDaniel, R.E.; Maximov, P.Y.; Fan, P.; Jordan, V.C. Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Horm. Mol. Biol. Clin. Investig., 2012, 9(2), 143-163.
16. Droog, M.; Beelen, K.; Linn, S.; Zwart, W. Tamoxifen resistance: from bench to bedside. Eur. J. Pharmacol., 2013, 717(1-3), 47-57.
17. Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R.A.; Will, M.; Li, Z.; Gala, K.; Fanning, S.; King, T.A.; Hudis, C.; Chen, D.; Taran, T.; Hortobagyi, G.; Greene, G.; Berger, M.; Baselga, J.; Chandarlapaty, S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet., 2013, 45(12), 1439-1445.
18. Robinson, D.R.; Wu, Y.M.; Vats, P.; Su, F.; Lonigro, R.J.; Cao, X.; Kalyana-Sundaram, S.; Wang, R.; Ning, Y.; Hodges, L.; Gursky, A.; Siddiqui, J.; Tomlins, S.A.; Roychowdhury, S.; Pienta, K.J.; Kim, S.Y.; Roberts, J.S.; Rae, J.M.; Van Poznak, C.H.; Hayes, D.F.; Chugh, R.; Kunju, L.P.; Talpaz, M.; Schott, A.F.; Chinnaiyan, A.M. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet., 2013, 45(12), 1446-1451.
19. Merenbakh-Lamin, K.; Ben-Baruch, N.; Yeheskel, A.; Dvir, A.; Soussan-Gutman, L.; Jeselsohn, R.; Yelensky, R.; Brown, M.; Miller, V.A.; Sarid, D.; Rizel, S.; Klein, B.; Rubinek, T.; Wolf, I. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res., 2013, 73(23), 6856-6864.
20. Johnston, S.R.; Saccani-Jotti, G.; Smith, I.E.; Salter, J.; Newby, J.; Coppen, M.; Ebbs, S.R.; Dowsett, M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res., 1995, 55(15), 3331-3338.
21. Gutierrez, M.C.; Detre, S.; Johnston, S.; Mohsin, S.K.; Shou, J.; Allred, D.C.; Schiff, R.; Osborne, C.K.; Dowsett, M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol., 2005, 23(11), 2469-2476.
22. Ottaviano, Y.L.; Issa, J.P.; Parl, F.F.; Smith, H.S.; Baylin, S.B. Davidson, N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 1994, 54, 2552-2555.
23. Lapidus, R.G.; Ferguson, A.T.; Ottaviano, Y.L.; Parl, F.F.; Smith, H.S.; Weitzman, S.A.; Baylin, S.B.; Issa, J.P.; Davidson, N.E. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res., 1996, 2(5), 805-810.
24. Lapidus, R.G.; Nass, S.J.; Butash, K.A.; Parl, F.F.; Weitzman, S.A.; Graff, J.G.; Herman, J.G.; Davidson, N.E. Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res., 1998, 58, 2515-2519.
25. Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; van der Groep, P.; Artemov, D.; Kowalski, J.; Carraway, H.; van Diest, P.; Raman, V. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene, 2012, 31(27), 3223-3234.
26. Yan, L.; Nass, S.J.; Smith, D.; Nelson, W.G.; Herman, J.G.; Davidson, N.E. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther., 2003, 2(5), 552-526.
27. Sharma, D.; Saxena, N.K.; Davidson, N.E.; Vertino, P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res., 2006, 66(12), 6370-6378.
28. Fleury, L.; Gerus, M.; Lavigne, A.C.; Richard-Foy, H.; Bystricky, K. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene, 2008, 27(29), 4075-4785.
29. Zhang, W.; Wang, L.; Fan, Q.; Wu, X.; Wang, F.; Wang, R.; Ma, Z.; Yang, J.; Lu, S.H. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo. Oncol. Rep., 2011, 26(3), 621-628.
30. Prat, A.; Adamo, B.; Cheang, M.C.; Anders, C.K.; Carey, L.A.; Perou, C.M. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist, 2013, 18(2), 123-133.
31. Iwao, K.; Miyoshi, Y.; Egawa, C.; Ikeda, N.; Tsukamoto, F.; Noguchi, S. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer, 2000, 89(8), 1732-1738.
32. Ma, X.J.; Hilsenbeck, S.G.; Wang, W.; Ding, L.; Sgroi, D.C.; Bender, R.A.; Osborne, C.K.; Allred, D.C.; Erlander, M.G. The HOXB13:IL17BR expression index is a prognostic factor in earlystage breast cancer. J. Clin. Oncol., 2006, 24(28), 4611-4619.
33. Chu, I.; Arnaout, A.; Loiseau, S.; Sun, J.; Seth, A.; McMahon, C.; Chun, K.; Hennessy, B.; Mills, G.B.; Nawaz, Z.; Slingerland, J.M. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J. Clin. Invest., 2007, 117(8), 2205-2215.
34. Zhou, W.; Slingerland, J.M. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat. Rev. Cancer, 2014, 14(1), 26-38.
35. Geng, F.; Wenzel, S.; Tansey, W.P. Ubiquitin and proteasomes in transcription. Annu. Rev. Biochem., 2012, 81, 177-201.
36. Hurtado, A.; Holmes, K.A.; Ross-Innes, C.S.; Schmidt, D.; Carroll, J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet., 2011, 43(1), 27-33.
37. Williams, C.M.; Scibetta, A.G.; Friedrich, J.K.; Canosa, M.; Berlato, C.; Moss, C.H.; Hurst, H.C. AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J. 2009, 28(22), 3591-3601.
38. Tan, S.K.; Lin, Z.H.; Chang, C.W.; Varang, V.; Chng, K.R.; Pan, Y.F.; Yong, E.L.; Sung, W.K.; Cheung, E. AP-2ã regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J., 2011, 30(13), 2569-2581.
39. Gee, J.M.; Eloranta, J.J.; Ibbitt, J.C.; Robertson, J.F.; Ellis, I.O.; Williams, T.; Nicholson, R.I.; Hurst, H.C. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J. Pathol., 2009, 217(1), 32-41.
40. Osborne, C.K.; Bardou, V.; Hopp, T.A.; Chamness, G.C.; Hilsenbeck, S.G.; Fuqua, S.A.; Wong, J.; Allred, D.C.; Clark, G.M.; Schiff, R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst., 2003, 95(5), 353-361.
41. Johnston, S.R.; Lu, B.; Scott, G.K.; Kushner, P.J.; Smith, I.E.; Dowsett, M.; Benz, C.C. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res., 1999, 5(2), 251-256.
42. Schiff, R.; Reddy, P.; Ahotupa, M.; Coronado-Heinsohn, E.; Grim, M.; Hilsenbeck, S.G.; Lawrence, R.; Deneke, S.; Herrera, R.; Chamness, G.C.; Fuqua, S.A.; Brown, P.H.; Osborne, C.K. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst., 2000, 92(23), 1926-1934.
43. Perkins, N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer, 2012, 12(2), 121-132.
44. Biswas, D.K.; Cruz, A.P.; Gansberger, E.; Pardee, A.B. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA., 2000, 97(15), 8542-8547.
45. Van Laere, S.J.; Van der Auwera, I.; Van den Eynden, G.G.; van Dam, P.; Van Marck, E.A.; Vermeulen, P.B.; Dirix, L.Y. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br. J. Cancer, 2007, 97(5), 659-669.
46. Hsu, S.M.; Chen, Y.C.; Jiang, M.C. 17 beta-estradiol inhibits tumor necrosis factor-alpha-induced nuclear factor-kappa B activation by increasing nuclear factor-kappa B p105 level in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun., 2000, 279(1), 47-52.
47. Cvoro, A.; Tzagarakis-Foster, C.; Tatomer, D.; Paruthiyil, S.; Fox, M.S.; Leitman, D.C. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol. Cell, 2006, 21(4), 555-564.
48. Belguise, K.; Sonenshein, G.E. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J. Clin. Invest., 2007, 117(12), 4009-4021.
49. Wang, X.; Belguise, K.; Kersual, N.; Kirsch, K.H.; Mineva, N.D.; Galtier, F.; Chalbos, D.; Sonenshein, G.E. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol., 2007, 9(4), 470-478.
50. Nettles, K.W.; Gil, G.; Nowak, J.; Métivier, R.; Sharma, V.B.; Greene, G.L. CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol. Endocrinol., 2008, 22(2), 263-272.
51. Wang, X.; Belguise, K.; O'Neill, C.F.; Sánchez-Morgan, N.; Romagnoli, M.; Eddy, S.F.; Mineva, N.D.; Yu, Z.; Min, C.; Trinkaus-Randall, V.; Chalbos, D.; Sonenshein, G.E. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol. Cell Biol., 2009, 29(14), 3832-3844.
52. Qiu, J.; Wang, X.; Guo, X.; Zhao, C.; Wu, X.; Zhang, Y. Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines. Oncol. Rep., 2009, 22(4), 935-941.
53. Park, K.J.; Krishnan, V.; O'Malley, B.W.; Yamamoto, Y.; Gaynor, R.B. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell, 2005, 18(1), 71-82.
54. Tu, Z.; Prajapati, S.; Park, K.J.; Kelly, N.J.; Yamamoto, Y.; Gaynor, R.B. IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J. Biol. Chem., 2006, 281(10), 6699-6706.
55. Pradhan, M.; Bembinster, L.A.; Baumgarten, S.C.; Frasor, J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J. Biol. Chem., 2010, 285(41), 31100-31106.
56. Frasor, J.; Weaver, A.; Pradhan, M.; Dai, Y.; Miller, L.D.; Lin, C.Y.; Stanculescu, A. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res., 2009, 69(23), 8918-8925.
57. Fan, C.; Oh, D.S.; Wessels, L.; Weigelt, B.; Nuyten, D.S.; Nobel, A.B.; van't Veer, L.J.; Perou, C.M. Concordance among geneexpression-based predictors for breast cancer. N. Engl. J. Med., 2006, 355(6), 560-569.
58. Paik, S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist, 2007, 12(6), 631-635.
59. Zhang, D.; Wang, G.; Wang, Y. Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data. BMC Bioinformatics, 2014, 15(Suppl 2), S10.
60. Kastrati, I.; Canestrari, E.; Frasor, J. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres. Oncogene, 2014, doi: 10.1038/onc.2014.180.
61. Tu, S.H.; Chang, C.C.; Chen, C.S.; Tam, K.W.; Wang, Y.J.; Lee, C.H.; Lin, H.W.; Cheng, T.C.; Huang, C.S.; Chu, J.S.; Shih, N.Y.; Chen, L.C.; Leu, S.J.; Ho, Y.S.; Wu, C.H. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res. Treat., 2010, 121(3), 539-553.
62. Zhou, Y.; Eppenberger-Castori, S.; Eppenberger, U.; Benz, C.C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer, 2005, 12 (Suppl 1), S37-46.
63. Sas, L.; Lardon, F.; Vermeulen, P.B.; Hauspy, J.; Van Dam, P.; Pauwels, P.; Dirix, L.Y.; Van Laere, S.J. The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res., 2012, 14(4), 212.
64. Oida, K.; Matsuda, A.; Jung, K.; Xia, Y.; Jang, H.; Amagai, Y.; Ahn, G.; Nishikawa, S.; Ishizaka, S.; Jensen-Jarolim, E.; Matsuda, H.; Tanaka, A. Nuclear factor-κB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci. Rep., 2014, 4, 4057.
65. Zhou, Y.; Yau, C.; Gray, J.W.; Chew, K.; Dairkee, S.H.; Moor,e D.H.; Eppenberger, U.; Eppenberger-Castori, S.; Benz, C.C. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 2007, 7, 59.
66. Nehra, R.; Riggins, R.B.; Shajahan, A.N.; Zwart, A.; Crawford, A.C.; Clarke, R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J., 2010, 24(6), 2040-2455.
67. Giordano, C.; Catalano, S.; Panza, S.; Vizza, D.; Barone, I.; Bonofiglio, D.; Gelsomino, L.; Rizza, P.; Fuqua, S.A.; Andò, S. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene, 2011, 30(39), 4129-4140.
68. Yde, C.W.; Emdal, K.B.; Guerra, B.; Lykkesfeldt, A.E. FκB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res. Treat., 2012, 135(1), 67-78.
69. Litchfield, L.M.; Appana, S.N.; Datta, S.; Klinge, C.M. OUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. Mol. Cell Endocrinol., 2014, 382(1), 358-367.
70. deGraffenried, L.A.; Chandrasekar, B.; Friedrichs, W.E.; Donzis, E.; Silva, J.; Hidalgo, M.; Freeman, J.W.; Weiss, G.R. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann. Oncol., 2004, 15(6), 885-890.
71. Trinh, X.B.; Sas, L.; Van Laere, S.J.; Prové, A.; Deleu, I.; Rasschaert, M.; Van de Velde, H.; Vinken, P.; Vermeulen, P.B.; Van Dam, P.A.; Wojtasik, A.; De Mesmaeker, P.; Tjalma, W.A.; Dirix, L.Y. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol. Rep., 2012, 27(3), 657-663.
72. Benz, C.C.; Scott, G.K.; Sarup, J.C.; Johnson, R.M.; Tripathy, D.; Coronado, E.; Shepard, H.M.; Osborne, C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 1992, 24(2), 85-95.
73. Chung, Y.L.; Sheu, M.L.; Yang, S.C.; Lin, C.H.; Yen, S.H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int. J. Cancer, 2002, 97(3), 306-312.
74. McClelland, R.A.; Barrow, D.; Madden, T.A.; Dutkowski, C.M.; Pamment, J.; Knowlden, J.M.; Gee, J.M.; Nicholson, R.I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology, 2001, 142(7), 2776-2788.
75. Cui, J.; Germer, K.; Wu, T.; Wang, J.; Luo, J.; Wang, S.C.; Wang, Q.; Zhang, X. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res., 2012, 72(21), 5625-5634.
76. Penault-Llorca, F.; Bertucci, F.; Adélai¨de, J.; Parc, P.; Coulier, F.; Jacquemier, J.; Birnbaum, D.; deLapeyrière, O. Expression of FGF and FGF receptor genes in human breast cancer. Int. J. Cancer, 1995, 61(2), 170-176.
77. Meijer, D.; Sieuwerts, A.M.; Look, M.P.; van Agthoven, T.; Foekens, J.A.; Dorssers, L.C. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr. Relat. Cancer., 2008, 15(1), 101-111.
78. Surmacz, E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia, 2000, 5(1), 95-105.
79. Yuan, T.L.; Cantley, L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene, 2008, 27, 5497-5510.
80. Simoncini, T.; Hafezi-Moghadam, A.; Brazil, D.P.; Ley, K.; Chin, W.W.; Liao, J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature, 2000, 407(6803), 538-541.
81. Campbell, R.A.; Bhat-Nakshatri, P.; Patel, N.M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem., 2001, 276(13), 9817-9824.
82. Yamnik, R.L.; Digilova, A.; Davis, D.C.; Brodt, Z.N.; Murphy, C.J.; Holz, M.K. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J. Biol. Chem., 2009, 284(10), 6361-6369.
83. Miller, T.W.; Hennessy, B.T.; González-Angulo, A.M.; Fox, E.M.; Mills, G.B.; Chen, H.; Higham, C.; García-Echeverría, C.; Shyr, Y.; Arteaga, C.L. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest., 2010, 120(7), 2406-2413.
84. Clark, A.S.; West, K.; Streicher, S.; Dennis, P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastu-zumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther., 2002, 1(9), 707-717.
85. deGraffenried, L.A.; Friedrichs, W.E.; Russell, D.H.; Donzis, E.J.; Middleton, A.K.; Silva, J.M.; Roth, R.A.; Hidalgo, M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res., 2004, 10(23), 8059-8067.
86. Bachelot, T.; Bourgier, C;, Cropet, C.; Ray-Coquard, I.; Ferrero, J.M.; Freyer, G.; Abadie-Lacourtoisie, S.; Eymard, J.C.; Debled, M.; Spae¨th, D.; Legouffe, E.; Allouache, D.; El Kouri, C.; Pujade-Lauraine, E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GI-NECO study. J. Clin. Oncol., 2012, 30(22), 2718-2724.
87. Creighton, C.J.; Fu, X.; Hennessy, B.T.; Casa, A.J.; Zhang, Y.; Gonzalez-Angulo, A.M.; Lluch, A.; Gray, J.W.; Brown, P.H.; Hilsenbeck, S.G.; Osborne, C.K.; Mills, G.B.; Lee, A.V.; Schiff, R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res., 2010, 12(3), R40.
88. Miller, T.W.; Rexer, B.N.; Garrett, J.T.; Arteaga, C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res., 2011, 13(6), 224.
89. Kalinsky, K.; Jacks, L.M.; Heguy, A.; Patil, S.; Drobnjak, M.; Bhanot, U.K.; Hedvat, C.V.; Traina, T.A.; Solit, D.; Gerald, W.; Moynahan, M.E. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res., 2009, 15(16), 5049-5059.
90. Ellis, M.J.; Lin, L.; Crowder, R.; Tao, Y.; Hoog, J.; Snider, J.; Davies, S.; DeSchryver, K.; Evans, D.B.; Steinseifer, J.; Bandaru, R.; Liu, W.; Gardner, H.; Semiglazov, V.; Watson, M.; Hunt, K.; Olson, J.; Baselga, J. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res. Treat., 2010, 119(2), 379-390.
91. Kalinsky, K.; Heguy, A.; Bhanot, U.K.; Patil, S.; Moynahan, M.E. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res. Treat., 2011, 129(2), 635-643.
92. Beelen, K.; Opdam, M.; Severson, T.M.; Koornstra, R.H.; Vincent, A.D.; Wesseling, J.; Muris, J.J.; Berns, E.M.; Vermorken, J.B.; van Diest, P.J.; Linn, S.C. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res., 2014, 16(1), R13.
93. Garcia-Echeverria, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27, 5511-5526.
94. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(23), 13513-13518.
95. Maehama, T.; Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem.,1998, 273(22), 13375-13378.
96. Stocker, H.; Andjelkovic Oldham, M.S.; Laffargue, M.; Wymann, M.P.; Hemmings, B.A.; Hafen, E. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science, 2002, 295, 2088-2091.
97. Hariharan, I.K.; Bilder, D. Regulation of imaginal disc growth by tumor-suppressor genes in drosophila. Annu. Rev. Genet., 2006, 40, 335-361.
98. Di Cristofano, A.; Pesce, B.; Cordon-Cardo, C.; Pandolfi, P.P. Pten is essential for embryonic development and tumour suppression. Nat.Genet., 1998, 19, 348-355.
99. Freeman, D.; Lesche, R.; Kertesz, N.; Wang, S.; Li, G.; Gao, J.; Groszer, M.; Martinez-Diaz, H.; Rozengurt, N.; Thomas, G.; Liu, X.; Wu, H. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res., 2006, 66, 6492-6496.
100. Podsypanina, K.; Ellenson, L.H.; Nemes, A.; Gu, J.; Tamura, M.; Yamada, K.M.; Cordon-Cardo, C.; Catoretti, G.; Fisher, P.E.; Parsons, R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci.U.S.A., 1996, 96, 1563-1568.
101. Stambolic, V.; Tsao, M.S.; Macpherson, D.; Suzuki, A.; Chapman, W.B.; Mak, T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res., 2000, 60, 3605-3611.
102. Suzuki, A.; de la Pompa, J.L.; Stambolic, V.; Elia, A.J.; Sasaki, T.; del BB, I.; Ho, A.; Wakeham, A.; Itie, A.; Khoo, W.; Fukumoto, M.; Mak, T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol., 1998, 8, 1169-1178.
103. Miller, T.W.; Pérez-Torres, M.; Narasanna, A.; Guix, M.; Stål, O.; Pérez-Tenorio, G.; Gonzalez-Angulo, A.M.; Hennessy, B.T.; Mills, G.B.; Kennedy, J.P.; Lindsley, C.W.; Arteaga, C.L. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res., 2009, 69(10), 4192-4201.
104. Fine, B.; Hodakoski, C.; Koujak, S.; Su, T.; Saal, L.H.; Maurer, M.; Hopkins, B.; Keniry, M.; Sulis, M.L.; Mense, S.; Hibshoosh, H.;Parsons, R. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science, 2009, 325(5945), 1261-1265.
105. He, L.; Ingram, A.; Rybak, A.P.; Tang, D. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J. Clin. Invest., 2010, 120(6), 2094-2108.
106. He, L.; Fan, C.; Kapoor, A.; Ingram, A.J.; Rybak, A.P.; Austin, R.C.; Dickhout, J.; Cutz, J.C.; Scholey, J.; Tang, D. α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat. Commun., 2011, 2, 307.
107. De Melo, J.; He, L.; Tang, D. The protein-protein interaction-mediated inactivation of PTEN. Curr. Mol. Med., 2014, 14(1), 22-33.
108. Sachdeva, M.; Wu, H.; Ru, P.; Hwang, L.; Trieu, V.; Mo, Y.Y. MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene, 2011, 30(7), 822-831.
109. Phuong, N.T.; Kim, S.K.; Lim, S.C.; Kim, H.S.; Kim, T.H.; Lee, K.Y.; Ahn, S.G.; Yoon, J.H.; Kang, K.W. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res. Treat., 2011, 130(1), 73-83.
110. Tanic, N.; Milovanovic, Z.; Tanic, N.; Dzodic, R.; Juranic, Z.; Susnjar, S.; Plesinac-Karapandzic, V.; Tatic, S.; Dramicanin, T.; Davidovic, R.; Dimitrijevic, B. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biol. Ther., 2012, 13(12), 1165-1174.
111. Garcia, J.M.; Silva, J.M.; Dominguez, G.; Gonzalez, R.; Navarro, A.; Carretero, L.; Provencio, M.; España, P.; Bonilla, F. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res. Treat., 1999, 57(3), 237-243.
112. Bose, S.; Wang, S.I.; Terry, M.B.; Hibshoosh, H.; Parsons, R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene, 1998, 17(1), 123-7.
113. Singh, B.; Ittmann, M.M.; Krolewski, J.J. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer, 1998, 21(2), 166-171.
114. Milovanovic, Z.; Dzodic, R.; Susnjar, S.; Plesinac-Karapandzic, V.; Juranic, Z.; Tatic, S. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen. J. BUON., 2011, 16(1), 46-51.
115. Shoman, N.; Klassen, S.; McFadden, A.; Bickis, M.G.; Torlakovic, E.; Chibbar, R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod. Pathol., 2005, 18(2), 250-209.
116. Lindberg, K.; Helguero, L.A.; Omoto, Y.; Gustafsson, J.Å.; Haldosén, L.A. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res., 2011, 13(2), R43.
117. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
118. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3, 730-737.
119. Visvader, J.E.; Lindeman, G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer, 2008, 8, 755-768.
120. Greaves, M. Cancer stem cells as 'units of selection'. Evol. Appl., 2013, 6, 102-108.
121. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5, 275-84.
122. Cojoc, M.; Ma¨bert, K.; Muders, M.H.; Dubrovska, A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin. Cancer Biol., 2014, pii: S1044-579X(14)00079-0. doi: 10.1016/j.
123. Vlashi, E.; Pajonk, F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol. 2014, pii: S1044-579X(14)00083-2. doi: 10.1016/j.semcancer.2014.07.001
124. Nieto, M.A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science, 2013, 342, 1234850.
125. Blanpain, C.; Fuchs, E. Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science, 2014, 344, 1242281.
126. Pece, S.; Tosoni, D.; Confalonieri, S.; Mazzarol, G.; Vecchi, M.; Ronzoni, S.; Bernard, L.; Viale, G.; Pelicci, P.G.; Di Fiore, P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 2010, 140(1), 62-73.
127. Wang, X.; Wang, G.; Zhao, Y.; Liu, X.; Ding, Q.; Shi, J.; Ding, Y.; Wang, S. STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J. Biomed. Res., 2012, 26(5), 325-335.
128. Dubrovska, A.; Hartung, A.; Bouchez, L.C.; Walker, J.R.; Reddy, V.A.; Cho, C.Y.; Schultz, P.G. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br. J. Cancer, 2012, 107(1), 43-52.
129. Raffo, D.; Berardi, D.E.; Pontiggia, O.; Todaro, L.; de Kier Joffé, E.B.; Simian, M. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res, Treat., 2013, 142(3), 537-48.
130. Piva, M.; Domenici, G.; Iriondo, O.; Rábano, M.; Simões, B.M.; Comaills, V.; Barredo, I.; López-Ruiz, J.A.; Zabalza, I.; Kypta, R.; Vivanco, Md. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol. Med., 2014, 6(1), 66-79.
131. Loh, Y.N.; Hedditch, E.L.; Baker, L.A.; Jary, E.; Ward, R.L.; Ford, C.E. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer, 2013, 13, 174.
132. Lombardo, Y.; Faronato, M.; Filipovic, A.; Vircillo, V.; Magnani, L.; Coombes, R.C. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res., 2014, 16(3), R62.
133. Ablett, M.P.; O'Brien, C.S.; Sims, A.H.; Farnie, G.; Clarke, R.B. A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget, 2014, 5(3), 599-612.
134. Lin, X.; Li, J.; Yin, G.; Zhao, Q.; Elias, D.; Lykkesfeldt, A.E.; Stenvang, J.; Brünner, N.; Wang, J.; Yang, H.; Bolund, L.; Ditzel, H.J. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res., 2013, 15(6), R119.
135. Kahn, M. Can we safely target the WNT pathway? Nat. Rev. Drug Discov., 2014, 13(7), 513-532.
136. Krausova, M.; Korinek, V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signal., 2014, 26(3), 570-579.
137. Boman, B.M.; Fields, J.Z. An APC:WNT Counter-current-like mechanism regulates cell division along the human colonic crypt axis: a mechanism that explains how APC mutations induce proliferative abnormalities that drive colon cancer development. Front Oncol., 2013, 3, 244.
138. Atlasi, Y.; Looijenga, L.; Fodde, R. Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective. Curr. Top. Dev. Biol., 2014, 107, 373-404.
139. Angeloni, V.; Tiberio, P.; Appierto, V.; Daidone, M.G. Implications of stemness-related signaling pathways in breast cancer response to therapy. Semin Cancer Biol., 2014, pii: S1044-579X(14)00101-1. doi: 10.1016/j.semcancer.2014.08.004.
140. Koch, U.; Lehal, R.; Radtke, F. Stem cells living with a Notch. Development, 2013, 140(4), 689-704.
141. Kushwah, R.; Guezguez, B.; Lee, J.B.; Hopkins, C.I.; Bhatia, M. Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human. EMBO Rep., 2014, 15(11), 1128-1138.
142. Raouf, A.; Zhao, Y.; To, K.; Stingl, J.; Delaney, A.; Barbara, M.; Iscove, N.; Jones, S.; McKinney, S.; Emerman, J.; Aparicio, S.; Marra, M.; Eaves, C. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell. Stem Cell, 2008, 3(1), 109-118.
143. Yalcin-Ozuysal, O.; Fiche, M.; Guitierrez, M.; Wagner, K.U.; Raffoul, W.; Brisken, C. Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell. Death Differ., 2010, 17(10), 1600-1612.
144. Ntziachristos, P.; Lim, J.S.; Sage, J.; Aifantis, I. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell, 2014, 25(3), 318-334.
145. Kondratyev, M.; Kreso, A.; Hallett, R.M.; Girgis-Gabardo, A.; Barcelon, M.E.; Ilieva, D.; Ware, C.; Majumder, P.K.; Hassell, J.A. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene, 2012, 31(1), 93-103.
146. Magnifico, A.; Albano, L.; Campaner, S.; Delia, D.; Castiglioni, F.; Gasparini, P.; Sozzi, G.; Fontanella, E.; Menard, S.; Tagliabue, E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res., 2009, 15(6), 2010-2021.
147. Yun, J.; Pannuti, A.; Espinoza, I.; Zhu, H.; Hicks, C.; Zhu, X.; Caskey, M.; Rizzo, P.; D'Souza, G.; Backus, K.; Denning, M.F.; Coon, J.; Sun, M.; Bresnick, E.H.; Osipo, C.; Wu, J.; Strack, P.R.; Tonetti, D.A.; Miele, L. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis, 2013, 2, e60.
148. Petrova, R.; Joyner, A.L. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development, 2014, 141(18), 3445-3457.
149. Campbell, V.; Copland, M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning, 2015, 8, 27-38.
150. Memmi, E.M.; Sanarico, A.G.; Giacobbe, A.; Peschiaroli, A.; Frezza, V.; Cicalese, A.; Pisati, F.; Tosoni, D.; Zhou, H.; Tonon, G.; Antonov, A.; Melino, G.; Pelicci, P.G.; Bernassola, F. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. U.S.A., 2015, 112(11), 3499-3504.
151. Sims-Mourtada, J.; Opdenaker, L.M.; Davis, J.; Arnold, K.M.; Flynn, D. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Mol. Carcinog., 2014, doi: 10.1002/mc.22225. [Epub ahead of print]
152. Ramaswamy, B.; Lu, Y.; Teng, K.Y.; Nuovo, G.; Li, X.; Shapiro, C.L.; Majumder, S. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res., 2012, 72(19), 5048-5059.
153. Arnold, K.; Sarkar, A.; Yram, M.A.; Polo, J.M.; Bronson, R.; Sengupta, S.; Seandel, M.; Geijsen, N.; Hochedlinger, K. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell, 2011, 9(4), 317-329.
154. Weina, K.; Utikal, J. SOX2 and cancer: current research and its implications in the clinic. Clin. Transl. Med., 2014, 3, 19.
155. Huang, Y.H.; Luo, M.H.; Ni, Y.B.; Tsang, J.Y.; Chan, S.K.; Lui, P.C.; Yu, A.M.; Tan, P.H.; Tse, G.M. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases. Histopathology, 2014, 64(4), 494-503.
156. Abd El-Maqsoud, N.M.; Abd El-Rehim, D.M. Clinicopathologic implications of EpCAM and Sox2 expression in breast cancer. Clin. Breast Cancer, 2014, 14(1), e1-9.
157. Leis, O.; Eguiara, A.; Lopez-Arribillaga, E.; Alberdi, M.J.; Hernandez-Garcia, S.; Elorriaga, K.; Pandiella, A.; Rezola, R.; Martin, A.G. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene, 2012, 31(11), 1354-1365.
158. Rodriguez-Pinilla, S.M.; Sarrio, D.; Moreno-Bueno, G.; Rodriguez-Gil, Y.; Martinez, M.A.; Hernandez, L.; Hardisson, D.; Reis-Filho, J.S.; Palacios, J. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod. Pathol., 2007, 20(4), 474-481.
159. Vazquez-Martin, A.; Cufí, S.; López-Bonet, E.; Corominas-Faja, B.; Cuyàs, E.; Vellon, L.; Iglesias, J.M.; Leis, O.; Martín, A.G.; Menendez, J.A. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle, 2013, 12(22), 3471-3477.
160. Stolzenburg, S.; Rots, M.G.; Beltran, A.S.; Rivenbark, A.G.; Yuan, X.; Qian, H.; Strahl, B.D.; Blancafort, P. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res., 2012, 40(14), 6725-6740.
161. Li, X.; Xu, Y.; Chen, Y.; Chen, S.; Jia, X.; Sun, T.; Liu, Y.; Li, X.; Xiang, R.; Li, N. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/βcatenin signal network. Cancer Lett., 2013, 336(2), 379-389.
162. Azzam, D.J.; Zhao, D.; Sun, J.; Minn, A.J.; Ranganathan, P.; Drews-Elger, K.; Han, X.; Picon-Ruiz, M.; Gilbert, C.A.; Wander, S.A.; Capobianco, A.J.; El-Ashry, D.; Slingerland, J.M. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ -secretase inhibitor drug responses. EMBO Mol. Med., 2013, 5(10), 1502-1522.
163. Mallepell, S.; Krust, A.; Chambon, P.; Brisken, C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc. Natl. Acad. Sci, U.S.A., 2006, 103(7), 2196-201.
164. Brisken, C.; Duss, S. Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev., 2007, 3(2), 147-56.
165. Clarke, R.B.; Howell, A.; Potten, C.S.; Anderson, E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res., 1997, 57(22), 4987-4991.
166. Russo, J.; Ao, X.; Grill, C.; Russo, I.H. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat., 1999, 53(3), 217-227.
167. Fillmore, C.M.; Gupta, P.B.; Rudnick, J.A.; Caballero, S.; Keller, P.J.; Lander, E.S.; Kuperwasser, C. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl. Acad. Sci. U.S.A., 2010,107(50), 21737-42.
168. Zhang, Y.; Eades, G.; Yao, Y.; Li, Q.; Zhou, Q. Estrogen receptor α signaling regulates breast tumor-initiating cells by downregulating miR-140 which targets the transcription factor SOX2. J. Biol. Chem., 2012, 287(49), 41514-41522.
169. Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J.B.; Liotta, .LA.; Petricoin, E 3rd.; Zhang, Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stemlike cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(41), 16158-16163.
170. Hardt, O.; Wild, S.; Oerlecke, I.; Hofmann, K.; Luo, S.; Wiencek, Y.; Kantelhardt, E.; Vess, C.; Smith, G.P.; Schroth, G.P.; Bosio, A.; Dittmer, J. Highly sensitive profiling of CD44+/CD24-breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway. Cancer Lett., 2012, 325(2), 165-174.
171. Gargini, R.; Cerliani, J.P.; Escoll, M.; Antón, I.M.; Wandosell, F. "Cancer stem cell-like phenotype and survival are coordinately regulated byakt/foxo/bim pathway". Stem Cells, 2014, doi: 10.1002/stem.1904.
172. Kolev, V.N.; Wright, Q.G.; Vidal, C.M.; Ring, J.E.; Shapiro, I.M.; Ricono, J.; Weaver, D.T.; Padval, M.V.; Pachter, J.A.; Xu, Q. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res., 2014, pii: canres.1223.2014.
173. Chang, W.W.; Lin, R.J.; Yu, J.; Chang, W.Y.; Fu, C.H., Lai, A.; Yu, J.C.; Yu, A.L. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res., 2013, 15(3), R39.
174. Coutu, D.L.; Galipeau, J. Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY), 2011, 3(10), 920-933.
175. Easton, D.F.; Pooley, K.A.; Dunning, A.M.; Pharoah, P.D.; Thompson, D.; Ballinger, D.G.; Struewing, J.P.; Morrison, J.; Field, H.; Luben, R.; Wareham, N.; Ahmed, S.; Healey, C.S.; Bowman, R. SEARCH collaborators, Meyer, K.B.; Haiman, C.A.; Kolonel, L.K.; Henderson, B.E.; Le Marchand, L.; Brennan, P.; Sangrajrang, S.; Gaborieau, V.; Odefrey, F.; Shen, C.Y.; Wu, P.E.; Wang, H.C.; Eccles, D.; Evans, D.G.; Peto, J.; Fletcher. O.; Johnson, N.; Seal, S.; Stratton, M.R.; Rahman. N.; Chenevix-Trench, G.; Bojesen, S.E.; Nordestgaard, B.G.; Axelsson, C.K.; Garcia-Closas, M.; Brinton, L.; Chanock, S.; Lissowska, J.; Peplonska, B.; Nevanlinna, H.; Fagerholm, R.; Eerola, H.; Kang, D.; Yoo, K.Y.; Noh, D.Y.; Ahn, S.H.; Hunter, D.J.; Hankinson, S.E.; Cox, D.G.; Hall, P.; Wedren, S.; Liu, J.; Low, Y.L.; Bogdanova, N.; Schürmann, P.; Dörk, T.; Tollenaar, R.A.; Jacobi, C.E.; Devilee, P.; Klijn, J.G.; Sigurdson, A.J.; Doody, M.M.; Alexander, B.H.; Zhang, J.; Cox, A.; Brock, I.W.; MacPherson, G.; Reed, M.W.; Couch. F.J.; Goode, E.; Olson, J.E.; Meijers-Heijboer, H.; van den Ouweland, A.; Uitterlinden, A.; Rivadeneira, F.; Milne, R.L.; Ribas, G.; Gonzalez-Neira, A.; Benitez, J.; Hopper, J.L.; McCredie, M.; Southey, M.; Giles, G.G.; Schroen, C.; Justenhoven, C.; Brauch, H.; Hamann, U.; Ko, Y.D.; Spurdle, A.B.; Beesley, J.; Chen, X.; kConFab; AOCS Management Group, Mannermaa, A.; Kosma, V.M.; Kataja, V.; Hartikainen, J.; Day, N.E.; Cox, D.R.; Ponder, B.A. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447(7148), 1087-1093.
176. Garcia-Closas, M.; Chanock, S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin. Cancer Res., 2008, 14(24), 8000-8009.
177. Courjal, F.; Cuny, M.; Simony-Lafontaine, J.; Louason, G.; Speiser, P.; Zeillinger, R.; Rodriguez, C.; Theillet, C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res., 1997, 57(19), 4360-4367.
178. Eccles, S.A. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int. J. Dev. Biol., 2011, 55(7-9), 685-696.
179. O'Brien, C.S.; Howell, S.J.; Farnie, G.; Clarke, R.B. Resistance to endocrine therapy: are breast cancer stem cells the culprits? J. Mammary Gland Biol. Neoplasia, 2009, 14(1), 45-54.
180. Korkaya, H.; Wicha, M.S. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res., 2013, 73(12), 3489-3493.
181. Korkaya, H.; Paulson, A.; Iovino, F.; Wicha, M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene, 2008, 27(47), 6120-6130.
182. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell. Stem Cell, 2007, 1(5), 555-567.
183. Duru, N.; Fan, M.; Candas, D.; Menaa, C.; Liu, H.C.; Nantajit, D.; Wen, Y.; Xiao, K.; Eldridge, A.; Chromy, B.A.; Li, S.; Spitz, D.R.; Lam, K.S.; Wicha, M.S.; Li, J.J. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res., 2012, 18(24), 6634-6647.
184. Ithimakin, S.; Day, K.C.; Malik, F.; Zen, Q.; Dawsey, S.J.; Bersano-Begey, T.F.; Quraishi, A.A.; Ignatoski, K.W.; Daignault, S.; Davis, A.; Hall, C.L.; Palanisamy, N.; Heath, A.N.; Tawakkol, N.; Luther, T.K.; Clouthier, S.G.; Chadwick, W.A.; Day, M.L.; Kleer, C.G.; Thomas, D.G.; Hayes, D.F.; Korkaya, H.; Wicha, M.S. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res., 2013, 73(5), 1635-46.
185. Paik, S.; Kim, C.; Wolmark, N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med., 2008, 358(13), 1409-1411.
186. Geng, S.Q.; Alexandrou, A.T.; Li, J.J. Breast cancer stem cells: Multiple capacities in tumor metastasis. Cancer Lett., 2014, 349(1), 1-7.
187. Hinohara, K.; Kobayashi, S.; Kanauchi, H.; Shimizu, S.; Nishioka, K.; Tsuji, E.; Tada, K.; Umezawa, K.; Mori, M.; Ogawa, T.; Inoue, J.; Tojo, A.; Gotoh, N. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc. Natl. Acad. Sci.U.S.A., 2012, 109(17), 6584-6589.
188. Liu, M.; Sakamaki, T.; Casimiro, M.C.; Willmarth, N.E.; Quong, A.A.; Ju, X.; Ojeifo, J.; Jiao, X.; Yeow, W.S.; Katiyar, S.; Shirley, L.A.; Joyce, D.; Lisanti, M.P.; Albanese, C.; Pestell, R.G. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res., 2010, 70(24), 10464-10473.
189. Pratt, M.A.; Tibbo, E.; Robertson, S.J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M.Y. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene, 2009, 28(30), 2710-2722.
190. Brantley, D.M.; Chen, C.L.; Muraoka, R.S.; Bushdid, P.B.; Bradberry, J.L.; Kittrell, F.; Medina, D.; Matrisian, L.M.; Kerr, L.D.; Yull, F.E. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell., 2001, 12(5), 1445-1455.
191. Merkhofer, E.C.; Cogswell, P.; Baldwin, A.S. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene, 2010, 29(8), 238-248.
192. Iliopoulos, D.; Hirsch, H.A.; Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 2009, 139(4), 693-706.
193. Lee, H.J.; Zhuang, G.; Cao, Y.; Du, P.; Kim, H.J.; Settleman, J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell, 2014, 26(2), 207-221.